Naiyareen F. Mayeen
Naiyareen F. Mayeen has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Aida Cardona-Alberich
Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Munich, Germany
1 shared publication - Anushka Jain1 shared publication
- Gamze Özata
LMU Munich
1 shared publication - Jennifer R. Hryhorenko
University of Rochester Mass Spectrometry Resource Laboratory, Rochester, NY, 14642, USA
1 shared publication - Kevin A. Welle
University of Rochester Mass Spectrometry Resource Laboratory, Rochester, NY, 14642, USA
1 shared publication - Kyle Swovick
University of Rochester Mass Spectrometry Resource Laboratory
1 shared publication
Latest Publications
- Open Access
Structural proteomics of the human ubiquitinome
The proteasome maintains the integrity of eukaryotic proteomes by selectively degrading ubiquitinated protein substrates. Ubiquitination targets a wide range of substrates for degradation, including translationally stalled nascent chains, misfolded proteins, and properly folded but short-lived proteins destined for regulatory degradation. Distinct structural features and ubiquitination patterns across these classes of substrates remain largely undefined. In this study, we combine structural proteomics and time-resolved isotopic labeling to profile the modification sites, dynamics, and conformational properties of the human ubiquitinome. We show that proteins undergoing rapid proteasomal degradation are ubiquitinated at lysine residues that are normally buried within structured regions of their native conformations. We provide proteome-wide evidence that this high-flux subset of the ubiquitinome is enriched in newly synthesized proteins that have non-native conformations. Together, our findings demonstrate how the lack of structural integrity of misfolded nascent proteins influences their ubiquitination patterns and ensures proper proteasomal degradation. Significance Statement: Protein degradation by the ubiquitin–proteasome system (UPS) is central to maintaining cellular protein quality control, yet the structural and kinetic determinants that govern which proteins are targeted for degradation remain poorly defined. Using deep-coverage structural proteomics combined with metabolic labeling, we show that ubiquitination events can be categorized into two broad classes with distinct properties: those at buried lysines within nascent misfolded proteins that lead to rapid proteasomal degradation, and those at exposed lysines in mature proteins that are associated with slower turnover or regulatory functions. This proteome-wide partitioning provides structural insights into how the UPS targets defective nascent and mature proteins for proteasomal clearance.
Open AccessStructural proteomics of the human ubiquitinome
The proteasome maintains the integrity of eukaryotic proteomes by selectively degrading ubiquitinated protein substrates. Ubiquitination targets a wide range of substrates for degradation, including translationally stalled nascent chains, misfolded proteins, and properly folded but short-lived proteins destined for regulatory degradation. Distinct structural features and ubiquitination patterns across these classes of substrates remain largely undefined. In this study, we combine structural proteomics and time-resolved isotopic labeling to profile the modification sites, dynamics, and conformational properties of the human ubiquitinome. We show that proteins undergoing rapid proteasomal degradation are ubiquitinated at lysine residues that are normally buried within structured regions of their native conformations. We provide proteome-wide evidence that this high-flux subset of the ubiquitinome is enriched in newly synthesized proteins that have non-native conformations. Together, our findings demonstrate how the lack of structural integrity of misfolded nascent proteins influences their ubiquitination patterns and ensures proper proteasomal degradation. Significance Statement: Protein degradation by the ubiquitin–proteasome system (UPS) is central to maintaining cellular protein quality control, yet the structural and kinetic determinants that govern which proteins are targeted for degradation remain poorly defined. Using deep-coverage structural proteomics combined with metabolic labeling, we show that ubiquitination events can be categorized into two broad classes with distinct properties: those at buried lysines within nascent misfolded proteins that lead to rapid proteasomal degradation, and those at exposed lysines in mature proteins that are associated with slower turnover or regulatory functions. This proteome-wide partitioning provides structural insights into how the UPS targets defective nascent and mature proteins for proteasomal clearance.
- Open Access
Multiomic profiling reveals aberrant immunomodulatory signature in β-propeller protein-associated neurodegeneration patient iPSC-derived microglia
Microglia are the primary immune cells of the central nervous system and play a crucial role in maintaining brain homeostasis. In common neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease (PD), early and sustained microglial activation has been shown to precede neuronal loss, with elevated levels of microglia-derived inflammatory mediators detected in affected brain regions. In contrast, little is known about the role of microglia in rare neurodegenerative disorders. One such disorder is β-propeller protein-associated neurodegeneration (BPAN), a common subtype of neurodegeneration with brain iron accumulation (NBIA). BPAN shares pathological features with PD, including iron accumulation and selective loss of dopaminergic neurons in the substantia nigra, and is caused by mutations in the WD repeat domain 45 (WDR45) gene encoding an autophagy protein also called WIPI4. However, the pathological role of mutant WDR45 in BPAN and the possible contribution of microglia remain unresolved. We generated the first BPAN patient microglia model system using induced pluripotent stem cells (iPSCs) to identify immune-related alterations and immunomodulatory signaling changes in a disease-relevant context. Integrated transcriptomic and proteomic profiling of iPSC-derived microglia from BPAN patients revealed a consistent shift from a homeostatic to a reactive, disease-associated state. Transcriptomic analysis showed disruption of core microglial pathways, including immune activation, stress response, and autophagy, consistent with a chronic pro-inflammatory phenotype. Complementary secretome analysis identified impaired lysosomal function and increased antigen presentation pathways, further supporting persistent microglial activation. Together this suggests that dysfunctional microglial states may contribute to BPAN pathogenesis. Our findings lay the groundwork for advancing immunomodulatory research in BPAN and may open new avenues for therapeutic development targeting microglial dysfunction.
Open AccessMultiomic profiling reveals aberrant immunomodulatory signature in β-propeller protein-associated neurodegeneration patient iPSC-derived microglia
Microglia are the primary immune cells of the central nervous system and play a crucial role in maintaining brain homeostasis. In common neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease (PD), early and sustained microglial activation has been shown to precede neuronal loss, with elevated levels of microglia-derived inflammatory mediators detected in affected brain regions. In contrast, little is known about the role of microglia in rare neurodegenerative disorders. One such disorder is β-propeller protein-associated neurodegeneration (BPAN), a common subtype of neurodegeneration with brain iron accumulation (NBIA). BPAN shares pathological features with PD, including iron accumulation and selective loss of dopaminergic neurons in the substantia nigra, and is caused by mutations in the WD repeat domain 45 (WDR45) gene encoding an autophagy protein also called WIPI4. However, the pathological role of mutant WDR45 in BPAN and the possible contribution of microglia remain unresolved. We generated the first BPAN patient microglia model system using induced pluripotent stem cells (iPSCs) to identify immune-related alterations and immunomodulatory signaling changes in a disease-relevant context. Integrated transcriptomic and proteomic profiling of iPSC-derived microglia from BPAN patients revealed a consistent shift from a homeostatic to a reactive, disease-associated state. Transcriptomic analysis showed disruption of core microglial pathways, including immune activation, stress response, and autophagy, consistent with a chronic pro-inflammatory phenotype. Complementary secretome analysis identified impaired lysosomal function and increased antigen presentation pathways, further supporting persistent microglial activation. Together this suggests that dysfunctional microglial states may contribute to BPAN pathogenesis. Our findings lay the groundwork for advancing immunomodulatory research in BPAN and may open new avenues for therapeutic development targeting microglial dysfunction.